regeneron.comRegeneron Pharmaceuticals: Delivering Life-transforming Medicines

Scientists Patients Medical Professionals Investors and Media Careers View our global site View our locations worldwide Canada EN | FR France FR | EN Germany DE | EN Ireland EN Italy IT | EN Japan 日本 | EN Netherlands NL | EN Spain ES | EN United Kingdom EN United States EN View our global site View our locations worldwide Canada EN | FR France FR | EN Germany DE | EN Ireland EN Italy IT | EN Japan 日本 | EN Netherlands NL | EN Spain ES | EN United Kingdom EN United States EN About Leadership Perspectives History Collaborations Our Locations Contact Us Science & Technology Research Areas Antibodies Genetic Medicines Technology Regeneron Genetics Center ® Scientific Publications Pipeline & Medicines Investigational Pipeline Approved Medicines Industrial Operations Investigational Clinical Trials Responsibility Improving Lives Integrity & Excellence Diversity, Equity & Inclusion Sustainable Communities Regeneron STS & ISEF Transparency & Policies Grants & Funding Scientists Patients Medical Professionals Investors and Media Careers Push the bounds of science Make life-changing medicines Pause Regeneron News: May 13th Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) Regeneron News: May 8th Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks Regeneron News: May 6th Regeneron Announces Investor Conference Presentations Follow us: Now approved for an expanded indication REGENERON PERSPECTIVES HITTING THE ON SWITCH” IN HEARING LOSS by: Meghan Drummond, PhD Director of Auditory Sciences, Regeneron Genetic Medicines Vassili Valayannopoulos, MD, PhD, MBA Clinical Program Lead, Auditory Sciences, Regeneron Genetic Medicines OUR ANNUAL MATERIALS PEOPLE, PERFORMANCE & PURPOSE Last year, we remained relentless in our quest to harness the power of science to improve patient lives. DISCOVER OUR YEAR IN REVIEW DOWNLOAD OUR RESPONSIBILITY REPORT DOWNLOAD OUR BETTER WORKPLACE. BETTER SCIENCE. BETTER WORLD. IMPACT REPORT Solving the human body’s most complex mysteries Scientific trailblazers Following the science leads to unexpected breakthroughs and diverse areas of study. Therapeutic Research Areas Developing new medicines for serious diseases A primarily ‘homegrown’ pipeline of potential medicines for dozens of diseases. Our Clinical Pipeline 35 years of challenges and triumphs Our story is unusual, with remarkable consistency of leadership and purpose in our efforts to accelerate the drug discovery and development process. MoreExplore our clinical trials The discoveries never stop as we work to help people with serious diseases. Clinical trials allow us to carefully test and collect data about investigational products before they can be approved for use. Learn more about our clinical trials or find a relevant one near you. Find trials Doing well by doing good Through responsible business practices and with the highest standards of integrity, we rise to any challenge with characteristic drive and a focus on scientific innovation. Our next generation of responsibility goals span three areas: Improving lives Integrity and excellence Sustainable Communities Moving at pandemic speed We’re applying our novel technologies to respond swiftly to public health infectious disease outbreaks like Ebola, MERS and COVID-19. Rapid Response Efforts Heroes of tomorrow Alumni of Regeneron’s STEM programs and competitions have won National Medals of Science, Fields Medals and Nobel Prizes. Our goal? Equip the next generation to keep the accolades, and the groundbreaking science, coming. Our Stem Programs Join our team Work with the brightest and most passionate minds in science. Apply to jobs and internships at Regeneron. Career Opportunities Sequencing the next million The Regeneron Genetics Center ® is working to solve the body’s most complex mysteries, because curiosity is in our genes. Antibody pioneers Discover the past, present and future of antibody medicine. Physician-scientists. Founders. A place where scientists are heroes. Meet our leaders. Citizens of science Transparency is a hallmark of scientific progress. See what our colleagues have published recently. × Close Open Transcript Close Transcript At Regeneron, we’ve been committed to making a difference in patients’ lives for over 30 years. We’ve done this by following the science. One of the things that’s made Regeneron really unique is its willingness to invest in cutting edge technologies. We’re one of the few companies in the world that go all the way from foundational discovery, to research, from research to development, to manufacturing and commercialization. We do that all at our campuses in New York, New Jersey, Ireland, and the UK. It’s really cool because we go from the really big thought, the really big idea, all the way to seeing the impact on a person. One of the things that distinguishes Regeneron is that we are a founder-led organization. Both Len and George are scientists, and they’ve really set the tone of focusing on science from the very beginning. And it spreads the through the organization in terms of our mission, our vision, our activities, our behaviors. We’re one of the unique places where we’ve put such a big emphasis on human genetics and deep biology. Our genetics research is focused on looking at differences in our genes and connecting that to diseases. We have a capability of combining human gene sequence data with electronic medical records. We have a rich genomic database, and we apply that across our organization, looking for new for new insights and to advance our research programs. We’ve invested in a set of core technologies we call the VelociSuite Technologies. These include things like VelociGene , VelocImmune , and together this suite of technologies gives us an engine for drug discovery. We can use that engine again, and again, and again to produce new drugs. Our VelociGene technologies give us an unprecedented ability to precisely manipulate the mouse genome and work very rapidly. Likewise, the VelocImmune technology gives us an unprecedented speed in producing new drugs candidates. So at a high level in drug development, there are really three key questions that we need to answer. One is does it work? Is it safe? And the third is can we produce it? Before we can even start to explore whether it works, part of the role in pre-clinical development is to establish whether it’s safe and also develop a manufacturing process by which we can produce it. So, I see ourselves as a link between the discovery world and the manufacturing facility where they will produce the drugs that we can test in clinical trials and ultimately also do commercial production. Once we’ve completed pre-clinical research to confirm safety, we work internally with our medical experts to develop our trial designs. We take those designs and work with healthcare providers across the globe to help us implement clinical trials. After decades of research at a lab bench and years of clinical trial work, we take tremendous pride in being able to determine whether we’ve made a difference in patient lives. After completion of our clinical trials and data analysis, we then take that data to regulatory authorities across the globe, so that they can give us our stamp of approval. With this approval, we work with our manufacturing group to switch into high gear. All of our drugs, whether they’re for a clinical trial or a commercial market, are made across our manufacturing footprint, in both Rensselaer, New York and Raheen, Ireland. Our quality standard is very simple. We want to make something that at the end of the day, we would put in ourselves, our children, our siblings, our parents, our grandparents and we have a just tremendous responsibility to get things that are safe and efficacious...